|
GSK Files For Approval Of Mepolizumab In US, Europe For Eosinophilic Asthma
Nasdaq The submissions include a Biologics Licence Application to the US Food and Drug Administration as an add-on maintenance treatment for severe eosinophilic asthma in patients aged 12 years and older with a history of exacerbations. It also comprises a … |
View full post on asthma – Google News